Physician profile
Brian N Maddux
NPI 1649298001
$7,123.51
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,944 · 2020: $830 · 2021: $458 · 2022: $587 · 2023: $321 · 2024: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260 · Education: $44.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.34 |
| Education | $44.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $930.33 | 2019-2024 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Abbott Laboratories | $529.17 | 2019-2024 | Infinity |
| Genzyme Corporation | $439.36 | 2019-2020 | |
| Acorda Therapeutics, INC | $395.01 | 2019-2020 | |
| Biogen, INC. | $394.48 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $372.87 | 2019-2020 | |
| Ucb, INC. | $346.01 | 2019-2020 | |
| Kyowa Kirin, INC. | $312.11 | 2019-2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $308.92 | 2019 | |
| Allergan, INC. | $280.50 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $262.96 | 2019-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $244.40 | 2019-2023 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $197.48 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $160.65 | 2019 | |
| Abbvie INC. | $160.54 | 2019-2024 |
Show all 48 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Maddux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.